GSK3003891A
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GSK3003891A, covering 2018-11-20 to 2018-11-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women [Phase 2]